Researchers have found that adding goserelin to chemotherapy significantly reduces early risk. menopause To breast cancer Increased the likelihood that patients and survivors will get Pregnant Later I will give birth to a healthy baby.
Goserelin (Zoladex) According to Dr. Kathy Alban, Principal Investigator at Loyola University Medical Center in Maywood, Illinois, the ovaries are temporarily “rested” during chemotherapy.
The study included 257 premenopausal women under the age of 50 in the early stages. estrogen-Or Progesterone-Receptor negative breast cancer.. Patients were randomly assigned to receive either standard chemotherapy or chemotherapy and goserelin.
Two years later, 45% of women in the chemotherapy-only group showed early signs menopause, Compared to only 20 percent of them chemical treatment Plasgoserelin Group. In addition, the author states: pregnancy It was 11% in the chemotherapy-only group and 21% in the goserelin group.
Four years later, 89% of women chemical treatment Plasgoserelin group showed no signs or symptoms cancerCompared to 78% of the chemotherapy-only group. According to the report, 4-year survival was 92% in the goserelin group and 82% in the chemotherapy-only group.
The findings will be presented at the Annual Meeting of the American Clinical Society on Saturday. Oncology (ASCO) was held in Chicago. Studies presented at the conference are considered preliminary until published in a peer-reviewed medical journal.
Goserelin is an injectable drug that resembles the natural hormones that the body makes.It is approved by the U.S. Food and Drug Administration for the treatment of Prostate cancer, Certain benign gynecological disorders and certain breast cancers.
Copyright © 2014 Health Day. all rights reserved.
Source: Loyola University, News Release, May 30, 2014
Drugs may reduce the chances of premature menopause in breast cancer patients
Source link Drugs may reduce the chances of premature menopause in breast cancer patients